GLP-1 receptor agonist treatment decreased hospitalization for heart failure by 9%, all-cause mortality by 12% and broad composite kidney results (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate, progression to end-stage kidney disease, or death attributable to kidney causes) by 17%, primarily as a result of decreased urinary albumin excretion [93]. Here, GLP1R is linked to heart failure.